{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:45Z","timestamp":1786980105982,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharmaceuticals AG and led by Novartis Pharmaceuticals Canada."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response. PURE is a multi-national, prospective, observational study in patients with moderate to severe chronic plaque psoriasis in Canada and Latin America, assessing the real-world safety and effectiveness of secukinumab and other indicated therapies. The aim of the current snapshot analysis was to evaluate the effectiveness and safety of on-label dose and updosed secukinumab in patients with plaque psoriasis enrolled in the PURE study. At the time of analysis, 676 patients received secukinumab, of which 84.6% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009572) remained on the on-label dose, while 15.4% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009104) were updosed. With on-label secukinumab, the absolute Psoriasis Area and Severity Index (PASI) score was reduced from 13.6 at baseline to 1.2 over 36 months, with treatment persistence of 73% at 40 months. At Month 36, 73.2% of the patients receiving on-label secukinumab achieved Investigator\u2019s Global Assessment (IGA) 0\/1. With updosed secukinumab (300\u00a0mg every 2 weeks, 300\u00a0mg every 3 weeks, 450\u00a0mg every 4 weeks, or 450\u00a0mg every 3 weeks), 57.9% of the patients showed improvement in the absolute PASI score at the first visit after updosing, with treatment persistence of 50% at 12 months after updosing. At Month 15, 40% of patients receiving updosed secukinumab achieved IGA 0\/1. Patients with previous biologic exposure (odds ratio [OR]:\u00a03.25; 95% confidence interval [CI]: 2.03, 5.18,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) were more likely to be updosed while those with a body weight\u2009&lt;\u200990\u00a0kg (OR: 0.49; 95% CI [0.31, 0.77],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0019) were less likely to be updosed. Previous biologic exposure (HR [hazard ratio]: 1.47; 95% CI [1.24, 1.75],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) and current biologic exposure (secukinumab vs. other indicated therapies: HR 0.57; 95% CI [0.43, 0.75],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0001) were significantly associated with time to secukinumab updosing. No new or unexpected safety signals were observed with updosed secukinumab. Secukinumab updosing was efficacious and well-tolerated in patients with psoriasis who failed to respond to the approved on-label regimen, suggesting that updosing may be a useful therapeutic option for approved dose non-responders.\n                  <\/jats:p>","DOI":"10.1007\/s00403-024-03122-w","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T05:02:07Z","timestamp":1717822927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry"],"prefix":"10.1007","volume":"316","author":[{"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Brassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Al-Mohammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haydey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Shayesteh","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Siddha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Maguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud S.","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Rihakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"3122_CR1","doi-asserted-by":"crossref","unstructured":"Parisi R, Iskandar IY, Kontopantelis E, Augustin M, Griffiths CE, Ashcroft DM (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. ;369","DOI":"10.1136\/bmj.m1590"},{"issue":"7","key":"3122_CR2","first-page":"CD011535","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L (2023) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 7(7):CD011535","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3122_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E (2014) Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med 371(4):326\u2013338","journal-title":"N Engl J Med"},{"issue":"26","key":"3122_CR4","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534\u20132548","journal-title":"N Engl J Med"},{"issue":"6 Suppl 1","key":"3122_CR5","first-page":"S12","volume":"9","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Vender R, Kircik L (2016) Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthetic Dermatol 9(6 Suppl 1):S12","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"4","key":"3122_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.15706","volume":"177","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, Mrowietz U (2017) Secukinumab sustains good efficacy and favourable safety in moderate-to\u2010severe psoriasis after up to 3 years of treatment: results from a double\u2010blind extension study. Br J Dermatol 177(4):1033\u20131042","journal-title":"Br J Dermatol"},{"issue":"10","key":"3122_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.18329","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, Ghislain PD, Torres T, Ioannides D, Aassi M, Schulz B (2022) Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate\u2010to\u2010severe plaque psoriasis: long\u2010term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol 36(10):1796\u20131804","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"3122_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZ Yiu","year":"2022","unstructured":"Yiu ZZ, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CE, Browne F, Evans I, Kleyn E (2022) Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatology 158(10):1131\u20131141","journal-title":"JAMA Dermatology"},{"issue":"4","key":"3122_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09546634.2019.1603361","volume":"31","author":"BE Strober","year":"2019","unstructured":"Strober BE, Germino R, Guana A, Greenberg JD, Litman HJ, Guo N, Lebwohl M (2019) US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J Dermatological Treat 31(4):333\u2013341","journal-title":"J Dermatological Treat"},{"key":"3122_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12895-019-0087-3","volume":"19","author":"KA Papp","year":"2019","unstructured":"Papp KA, Gooderham M, Beecker J, Lynde CW, Delorme I, Dei-Cas I, Albrecht L, Rampakakis E, Sampalis JS, Vieira A, Hussein S (2019) Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. BMC Dermatol 19:1\u20137","journal-title":"BMC Dermatol"},{"issue":"6","key":"3122_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P (2022) Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol 186(6):942\u2013954","journal-title":"Br J Dermatol"},{"issue":"2","key":"3122_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2023","unstructured":"Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R (2023) Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol 188(2):198\u2013207","journal-title":"Br J Dermatol"},{"issue":"6","key":"3122_CR13","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jaad.2019.04.045","volume":"81","author":"D Tha\u00e7i","year":"2019","unstructured":"Tha\u00e7i D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S (2019) Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study. J Am Acad Dermatol 81(6):1405\u20131409","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3122_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/jdv.14145","volume":"31","author":"M Esposito","year":"2017","unstructured":"Esposito M, Gisondi P, Conti A, Giunta A, Del Giglio M, Di Mercurio M, Veneziano L, Ferrucci G, Bianchi L, Chimenti S, Girolomoni G (2017) Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol 31(5):863\u2013869","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3122_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jdcr.2017.11.006","volume":"4","author":"M Phung","year":"2018","unstructured":"Phung M, Georgakopoulos JR, Ighani A, Giroux L, Yeung J (2018) Secukinumab dose optimization in adult psoriasis patients: a retrospective, multicenter case series. JAAD Case Rep 4(4):310\u2013313","journal-title":"JAAD Case Rep"},{"issue":"4","key":"3122_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/1203475419843118","volume":"23","author":"M Phung","year":"2019","unstructured":"Phung M, Ighani A, Georgakopoulos JR, Vender R, Giroux L, Lansang P, Yeung J (2019) Off-label high-dose secukinumab for the treatment of moderate-to-severe psoriasis. J Cutan Med Surg 23(4):391\u2013393","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"3122_CR17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjd.19398","volume":"184","author":"K Reich","year":"2021","unstructured":"Reich K, K\u00f6rber A, Mrowietz U, Sticherling M, Sieder C, Fr\u00fch J, Bachhuber T (2021) Secukinumab 2-weekly vs. 4\u2010weekly dosing in patients with plaque\u2010type psoriasis: results from the randomized GAIN study. Br J Dermatol 184(5):849\u2013856","journal-title":"Br J Dermatol"},{"issue":"1","key":"3122_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cpt.1478","volume":"106","author":"JE Lee","year":"2019","unstructured":"Lee JE, Wang J, Florian J, Wang YM, Kettl D, Marcus K, Woitach A (2019) Effect of body weight on risk-benefit and dosing regimen recommendation of secukinumab for the treatment of moderate to severe plaque psoriasis. Clin Pharmacol Ther 106(1):78\u201380","journal-title":"Clin Pharmacol Ther"},{"key":"3122_CR19","doi-asserted-by":"publisher","first-page":"204062231984375","DOI":"10.1177\/2040622319843756","volume":"10","author":"TY Ger","year":"2019","unstructured":"Ger TY, Huang YH, Hui RC, Tsai TF, Chiu HY (2019) Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Therapeutic Adv Chronic Disease 10:2040622319843756","journal-title":"Therapeutic Adv Chronic Disease"},{"issue":"2","key":"3122_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5114\/ada.2020.94835","volume":"37","author":"A Kisielnicka","year":"2020","unstructured":"Kisielnicka A, Szczerkowska-Dobosz A, Nowicki R (2020) The influence of body weight of patients with chronic plaque psoriasis on biological treatment response. Adv Dermatology Allergology\/Post\u0119py Dermatologii i Alergologii 37(2):168\u2013173","journal-title":"Adv Dermatology Allergology\/Post\u0119py Dermatologii i Alergologii"},{"key":"3122_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, Burlando M, Mariani M, Parodi A, Peris K, De Simone C (2021) Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig 41:917\u2013925","journal-title":"Clin Drug Investig"},{"issue":"3","key":"3122_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjd.13814","volume":"173","author":"D Thaci","year":"2015","unstructured":"Thaci D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, Gong Y, Papavassilis C, STATURE Study Group (2015) Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol 173(3):777\u2013787","journal-title":"Br J Dermatol"},{"issue":"1","key":"3122_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1203475417721424","volume":"22","author":"J Beecker","year":"2018","unstructured":"Beecker J, Joo J (2018) Treatment of moderate to severe psoriasis with high-dose (450-mg) secukinumab: case reports of off-label use. J Cutan Med Surg 22(1):86\u201388","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"3122_CR24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1080\/09546634.2020.1839009","volume":"33","author":"FE Y\u0131ld\u0131r\u0131m","year":"2022","unstructured":"Y\u0131ld\u0131r\u0131m FE, Hapa FA (2022) Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey. J Dermatological Treat 33(3):1531\u20131537","journal-title":"J Dermatological Treat"},{"issue":"2","key":"3122_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.18143","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R (2020) Secukinumab dosing optimization in patients with moderate-to\u2010severe plaque psoriasis: results from the randomized, open\u2010label OPTIMISE study. Br J Dermatol 182(2):304\u2013315","journal-title":"Br J Dermatol"},{"key":"3122_CR26","unstructured":"Cosentyx product monograph (2022) https:\/\/pdf.hres.ca\/dpd_pm\/00067634.PDF Accessed 23 March 2023"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03122-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03122-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03122-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:30:00Z","timestamp":1725899400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03122-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3122"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03122-w","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,8]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent to participate in the study. The study design was reviewed and approved by the ethics committees or institutional review boards, and the study was conducted in accordance with the principle of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Kim A. Papp serves as a consultant for AbbVie, Akros, Amgen, Arcutis, Atellas, Avillion, Bausch Health\/Valeant, Baxalta, Boehringer Ingelheim, Can-Fite Biopharma, Coherus, Dermavant, Dermira, Dow Pharma, Eli Lilly and Company, Evelo, Galapagos, Galderma, Genentech, Incyte, Janssen, Kyowa Hakko Kirin, Leo Pharma A\/S, Merck (MSD), Merck Serono, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis\/Genzyme, Takeda and UCB; received research grants from Anacor, Gilead, GSK, MedImmune, Moberg Pharma and Sun Pharmaceuticals; is a scientific officer for Akros, Anacor, Arcutis, Dice Pharmaceuticals and Kyowa Hakko Kirin; is a consultant for Dice Pharmaceuticals, Meiji Seika Pharma and Mitsubishi Pharma; is a speaker, received honoraria and participated in steering committees and advisory boards for AbbVie, Amgen, Bausch Health\/Valeant, Celgene, Eli Lilly and Company, Janssen, Merck (MSD), Novartis, Pfizer and Sanofi-Aventis\/Genzyme. Melinda Gooderham serves as a speaker, an investigator or an advisory board member for AbbVie, Amgen, Akros, Arcutis, Arena, Aslan, AnaptysBio, Apogee, Aristea, Bausch, Boehringer Ingelheim, BMS, Celgene, Coherus, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Meiji, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, Union, UCB and Ventyx. Charles Lynde serves as a speaker or consultant or advisor or investigator or received honoraria from AbbVie, Altius, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Devonian, Eli Lilly, Fresnius Kabi, Galderma, GSK, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Oreal, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. Danielle Brassard is a speaker and receives honoraria from AbbVie, Actelion, Bausch Health, Galderma, Janssen, Leo Pharma, Novartis, Pfizer and Sanofi; participates as a consultant for AbbVie, Amgen, Bausch Health, Celgene, Novartis and Pfizer; and acts as principal investigator for AbbVie, BMS, Bausch Health, Incyte, Leo Pharma, Novartis, Pfizer, Reistone and Sanofi. Faisal Al-Mohammedi is an investigator for Novartis, Jansen, Bausch, Abbvie and Incyte Pharma.Vimal H. Prajapati is an investigator for AbbVie, Amgen, AnaptysBio, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma, and Valeant; has served as a consultant, advisor and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, CorEvitas, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, Janssen, LEO Pharma, L\u2019Oreal, Medexus, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB Pharma, and Valeant; received grants from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Antonio Vieira and is a full-time employee at Novartis Pharmaceuticals Canada Inc. and Lenka Rihakova was a full-time employee at Novartis Pharmaceuticals Canada Inc. until final draft of this manuscript. Isabelle Delorme serves as a speaker or consultant, or received honoraria from Abbvie, Bausch Health, Amgen, Eli Lilly, Novartis, and Janssen. Lorne Albrecht serves as a speaker or consultant or advisor or investigator or received honoraria\/grants from AbbVie; Amgen; Arcutis; Bausch Health; Bristol-Myers-Squibb; Celgene; Eli Lilly; Galderma; Janssen; LEO Pharma; Novartis; Pfizer; Sanofi; UCB. Richard Haydey has been a consultant and advisor and\/or received speaking fees and\/or grants and\/or served as an investigator in clinical trials for the following companies: AbbVie, Amgen, Galderma, GSK, Leo, Lilly, Novartis, Merck, Pfizer, UCB and consulting fees from AbbVie, Amgen, Janssen, Galderma, GSK, Leo, Lilly, Novartis, Pfizer, Bausch-Health, Celgene and UCB. Maryam Shayesteh Alam have no conflict of interest. Jennifer Beecker serves as a consultant for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Sun Pharma, and UCB; is a speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Sun Pharma, and UCB; and received research grants from AbbVie, Amgen, Concert, Evelo, Incyte, Janssen, Leo Pharma, Novartis, Janssen, Leo Pharma, Novartis. Sanjay Siddha serves as an investigator for AbbVie, Amgen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, has served as a consultant, advisor and\/or speaker for AbbVie, Actelion, Amgen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, L\u2019Oreal, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB Pharma, and Valeant; received grants from Amgen, Astellas. Marie Maguin, Mahmoud S. Farag and Antonio Vierra are a full-time employee at Novartis Pharmaceuticals Canada Inc. Lenka Rihakova was a full-time employee at Novartis Pharmaceuticals Canada Inc. until the initial draft development of this manuscript. Richard Langley serves as an investigator, advisory board member, or speaker for AbbVie, Amgen, Bausch, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galderma, GSK, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharmaceuticals, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}